Sole US Patent Protecting Apriso Mesalamine Capsules Is Obvious
Executive Summary
In a ruling favouring Mylan, GeneriCo and Flat Line Capital, The US Court of Appeals has confirmed an inter partes review finding that key claims of the sole patent listed against Bausch Health’s Apriso mesalamine brand are unpatentable as obvious.
You may also be interested in...
Sun Outstrips Viatris’ Pentasa Action Date With First ANDA Approval
Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.
Deal With Bausch Allows Teva To Sell Generic Of Apriso In 2021
Bausch Health has settled its patent litigation with Teva over the Canadian firm’s ulcerative colitis medicine Apriso (mesalamine) 375mg extended-release capsules. The deal gives Teva the right to market a generic version of Apriso in the US in 2021, nine years before the patent on the drug expires.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.